Related Experiment Video
Updated: Jul 6, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes
Towfik Sebai1, Rebecca Hassoun1, Sandra Althouse1
1Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
Clinical Genitourinary Cancer
|July 4, 2026
Summary
Primary mediastinal pure seminoma shows excellent outcomes with cisplatin-based chemotherapy. Bleomycin is safe, and routine consolidative therapy or imaging may not be necessary for optimal results.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Primary mediastinal pure seminoma is a rare extragonadal germ cell tumor.
- Limited contemporary data exists on its treatment and outcomes.
- This study characterizes treatment patterns at a tertiary center.
Purpose of the Study:
- To evaluate treatment strategies for primary mediastinal pure seminoma.
- To assess oncologic outcomes, including progression-free survival (PFS) and overall survival (OS).
- To determine the safety of bleomycin administration in this patient population.
Main Methods:
- Retrospective cohort study of 24 patients diagnosed between 1994 and 2025.
- Analysis of clinical characteristics, treatment regimens, recurrence, and toxicity.
- Kaplan-Meier method used for PFS and OS estimation.
Main Results:
- Median age at diagnosis was 35.7 years; 54.2% presented with metastases.
- Five-year PFS was 86.2% and 5-year OS was 95.2%.
- No bleomycin-related pulmonary toxicity was observed; disease progression occurred within the mediastinum.
Conclusions:
- Front-line cisplatin-based chemotherapy yields excellent outcomes for primary mediastinal pure seminoma.
- Bleomycin can be safely used in this patient group.
- Routine consolidative radiotherapy, surgery, or post-chemotherapy PET imaging may not be required.
